Pharmaron Beijing Co., Ltd. Class H ( (HK:3759) ) has issued an update.

Pharmaron Beijing Co., Ltd. reported the results of its 2025 annual general meeting in Beijing, confirming that the meeting was validly convened under PRC law and its Articles of Association, with about 48.7% of voting shares represented. All directors attended, and independent scrutineers, including the H share registrar and the company’s PRC legal adviser, supervised the poll process in line with Hong Kong listing requirements.

Shareholders approved all ordinary resolutions, including the 2025 profit distribution and 2026 interim dividend plan, the 2025 annual report and results, director remuneration and a new remuneration policy, an estimated hedging quota for 2026, and the appointment of domestic and international auditors. The meeting also endorsed the election of a non-executive director to the fourth board and amendments to the Articles of Association, reinforcing Pharmaron’s governance framework and capital management plans for the coming year.

The most recent analyst rating on (HK:3759) stock is a Buy
with a HK$28.10 price target.
To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock,
see the HK:3759 Stock Forecast page.